Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers
Fri, 17 Aug Closing | Rini Mehta, TM Team

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points, while, NSE Nifty ended up by 86 points.

Except energy stocks, all sectoral indices ended the day in green with metal stocks and FMCG stocks leading the gainers.

Globally, Asian stock markets finished mixed as of the most recent closing prices. The Hang Seng gained 0.4% and the Nikkei 225 rose 0.4%. The Shanghai Composite lost 1.3%. European markets are mixed today. The CAC 40 is up 0.2% while the FTSE 100 gains 0.1%. The DAX is off 0.1%.

The rupee was trading at Rs 70.23 against the US$ in the afternoon session.

In the news from the pharma sector. As per an article in a leading financial daily, drug price regulator, the National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of 92 drug formulations used for treatment of cancer, hepatitis C, migraine and diabetes among others.

The prices have been fixed under the Drug (Prices Control) Order (DPCO), 2013.

The authority has mentioned that out of total, the retail price of 72 scheduled formulations has been fixed, that of 9 has been revised. It has also revised the retail prices of 11 scheduled formulations.

Under the Drugs (Prices Control) Order (DPCO) 2013, it fixes ceiling price of essential medicines of Schedule I based on simple average of all medicines in a particular therapeutic segment with sales of more than 1%.

In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10% annually.

Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and decontrolled drugs.

Speaking of Indian pharma sector, the leading therapy segments in terms of brand launches during FY13 to FY17 were dermatology, anti-infectives, cardiology, and gastroenterology. Anti-diabetics have also been growing in double-digits for the past five years.

However, with the government bringing a number of essential drugs under price control, prescription drugs are witnessing sluggish growth. Therefore, pharma companies are now focusing on the over-the-counter (OTC) medicines.

Thus, while pricing controls keep the operating environment tough in the domestic market, pharma companies with strong brands in the OTC category are better placed to ride the slowdown.

In another development, the India Ratings and Research (Ind-Ra), a subsidiary of Fitch Ratings, in its latest report has revised its Indian economic growth forecast to 7.2% for current fiscal year (FY19) from 7.4% forecasted earlier.

This revision came on the back of headwinds emanating from elevated global crude oil prices and the government's decision to fix the minimum support prices of all kharif crops at 1.5 times the production cost.

It also pointed to other headwinds lurking on the horizon such as the rising trade protectionism, depreciating rupee and, no visible signs of the abatement of the non-performing assets of the banking sector.

The report stated that it is taking a tad longer than expected to resolve cases under the Insolvency and Bankruptcy Code.

The report also expects private final consumption expenditure to grow 7.6% in 2018-19 compared to 6.6% in 2017-18. It pointed out that government capex alone will be insufficient to revive the capex cycle, as its share in the total capex of the economy was only 11.1% during 2012-17.

The rating agency observed that the share of private corporations was 40.9%. As private corporations in combination with the household sector command 77.5% of the total investment in the economy, their capex revival is a must for a broad-based recovery in the investment cycle.

Noting that India will face continued headwinds on the exports front, it said although it expects the annual value of exports to touch US$345 billion in the current fiscal, crossing the peak of US$318 billion attained in 2013-14.

On the inflation front, it expects average retail and wholesale inflation in 2018-19 to come in at 4.6% and 4.1%, respectively, as against 4.3% and 3.4% forecasted earlier. It also expects current account deficit (CAD) to widen to US$71.1 billion in 2018-19 from US$48.7 billion in 2017-18.

On rupee, it said that in 2018, rupee has already depreciated 7.7% till July in response to elevated global turbulence, worsening of current account, rising inflation and concerns related to fiscal deficit.

Besides, Ind-Ra has maintained a stable outlook on the finances of Indian states for 2018-19 and expects the aggregate fiscal deficit of the states to moderate to 2.8% of GDP.

Meanwhile, note that, by clocking 7.7% growth in the March quarter, India has regained the title of 'world's fastest-growing major economy'.

India's GDP Growth is Back on Track

We at Equitymaster, were in wait and watch mode. But now, we believe, the revival in the economy is truly underway. A good monsoon will only add to the momentum.

However, we must point out, the revival is not complete. It has been driven by government spending and private sector consumption. Capital investments and exports are yet to pick up. Only when these engines start firing will we achieve 9%+ growth.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

You can listen to this week's stock market updates in our brand new podcast below. Tune in!

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers". Click here!


Stock Market Updates

Most Active Small-Cap Stocks Today; KAVERI SEED the Most Traded (Today's Market)

Feb 19, 2019 04:54 PM

Here's a list of most active small-cap stocks today. It also includes information on BSE Smallcap index and the broader benchmark indices.

Top 5 Mid-Cap Gainers Today; EMAMI LTD Leads the Pack (Today's Market)

Feb 19, 2019 04:53 PM

Here's a list of 5 stocks that gained the most in the BSE Mid-Cap Index today. It also includes information on BSE Mid-Cap index and the broader benchmark indices.

The BSE IT Index Down 2% ; GENESYS INTL. Among Top Losers (Today's Market)

Feb 19, 2019 03:08 PM

The BSE IT Index Down at 15,188 (down 2.0%). Among the top losers in the BSE IT Index today are GENESYS INTL., L&T TECHONOLOGY SERVICES and TCS. Meanwhile, the BSE Sensex has plunged 0.3% to 35,776.

SHARDA CROPCHEM Surges by 18%; BSE 500 Index Up 0.1% (Today's Market)

Feb 19, 2019 03:04 PM

SHARDA CROPCHEM share price has surged by 18% and its current market price is Rs 381. The BSE 500 is up by 0.1%. The top gainers in the BSE 500 Index are SHARDA CROPCHEM (up 18.0%) and EMAMI LTD (up 15.0%). The top losers are OMAXE LTD and ASIAN PAINTS .

INDIABULLS VENTURES Plunges by 5%; BSE 500 Index Up 0.6% (Today's Market)

Feb 19, 2019 02:46 PM

INDIABULLS VENTURES share price has plunged by 5% and its current market price is Rs 274. The BSE 500 is up by 0.6%. The top gainers in the BSE 500 Index are EMAMI LTD (up 15.9%) and WELSPUN CORP (up 9.0%). The top losers are INDIABULLS VENTURES (down 5.2%) and IFB INDUSTRIES LTD (down 5.1%).

Sensex Trades Marginally Higher; Vedanta & Bharti Airtel Top Gainers (Today's Market)

Feb 19, 2019 12:30 pm

The BSE Sensex is trading up by 136 points, while the NSE Nifty is trading up by 37 points.

View More Indian Share Market News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Feb 19, 2019 (Close)